Germany
· Delayed Price · Currency is EUR | Market Cap | 875.04M |
| Revenue (ttm) | 523.70M |
| Net Income (ttm) | 180.66M |
| Shares Out | n/a |
| EPS (ttm) | 0.80 |
| PE Ratio | 4.84 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,339 |
| Average Volume | 60,565 |
| Open | 3.830 |
| Previous Close | 3.950 |
| Day's Range | 3.750 - 3.990 |
| 52-Week Range | 2.170 - 4.950 |
| Beta | n/a |
| RSI | 58.70 |
| Earnings Date | Aug 15, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad... [Read more]
Financial Performance
Financial StatementsNews
CureVac BV reports Q1 results
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...
CureVac Unveils Q1 2025 Financial Results & Business Updates!
CureVac is forging ahead with innovative clinical trials and strategic patent victories, positioning itself for a promising future in the biotech industry. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates 20.05.2025 / 13:00 CET/CEST The issuer is solely responsi...
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac BV reports Q4 results
CureVac N.V. 2024 Q4 - Results - Earnings Call Presentation
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precisio...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi...
CureVac: 2024 Financial Results & Business Update Unveiled
CureVac is making strides in medical innovation, with promising studies and robust financial growth marking a transformative year. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Issuer: CureVac / Key word(s): Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solel...
Earnings Scheduled For April 10, 2025
Companies Reporting Before The Bell • CureVac (NASDAQ: CVAC) is likely to report quarterly loss at $0.09 per share on revenue of $20.58 million. • CarMax (NYSE: KMX) is projected to report quarterly...
Insights Ahead: CureVac's Quarterly Earnings
CureVac (NASDAQ: CVAC) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement. Analysts estimate that CureVac will rep...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...
CureVac's 2024 Financial Results & Key Updates: April 10 Reveal
Discover CureVac's 2024 financial insights on April 10, 2025, as the mRNA pioneer shares its global achievements and future outlook. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Issuer: CureVac / Key word(s): Annual Results CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 08.04.2025 / 13:00 CET/CEST The issuer is sole...
CureVac to initiate Phase 1 trial for its lung cancer therapy
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerProprietary Epitopes: CVHNLC encodes novel...
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove...
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Issuer: CureVac / Key word(s): Study/Regulatory Approval CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small C...